Evidence map›Paper›PMID 26645692›Full record

ArticleThe Journal of biological chemistry2016

Interferon γ (IFNγ) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses.

Barbara Kroczynska, Robert L Rafidi, Beata Majchrzak-Kita, Ewa M Kosciuczuk, Gavin T Blyth, Jacek Jemielity, Zofia Warminska, Diana Saleiro, Swarna Mehrotra, Ahmet Dirim Arslan and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Interferon-Gamma-Mediated Osteoimmunology.Frontiers in immunology · 2018
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Barbara KroczynskaFrom the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Department of Radiation Oncology, Northwestern University, Chicago, Illinois 60611.
Robert L RafidiFrom the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.
Beata Majchrzak-Kitathe Toronto General Research Institute, University Health Network, and Department of Immunology, University of Toronto, Toronto, Ontario M5G 2MI, Canada.
Ewa M KosciuczukFrom the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612.
Gavin T BlythFrom the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.
Jacek Jemielitythe Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland, and.
Zofia Warminskathe Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland, and the College of Inter-Faculty Individual Studies in Mathematics and Natural Sciences, University of Warsaw, 02-089 Warsaw, Poland.
Diana SaleiroFrom the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.
Swarna MehrotraFrom the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.
Ahmet Dirim ArslanFrom the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.
Eleanor N Fishthe Toronto General Research Institute, University Health Network, and Department of Immunology, University of Toronto, Toronto, Ontario M5G 2MI, Canada.
Leonidas C PlataniasFrom the Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, the Division of Hematology-Oncology, Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612, l-platanias@northwestern.edu.
Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityNorthwestern University · USUniversity Health Network · CACollege of Europe, Warsaw · PLJesse Brown VA Medical Center · USUniversity of Warsaw · PL

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
Signal Transduction of Type I Interferons in Malignant CellsR01CA077816 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 1998 to 2024
$6.6M
TRAINING PROGRAM IN SIGNAL TRANSDUCTION AND CANCERT32CA070085 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1997 to 2026
$5.7M
TRAINING PROGRAM IN ONCOGENESIS &DEVELOPMENT BIOLOGYT32CA080621 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI EKLUND, ELIZABETH ANN · 2001 to 2018
$4.1M
Mnk Pathways and IFN-responses in Malignant CellsR01CA155566 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 2011 to 2015
$1.6M
Interferon-induced SLFNs and tumorigenesisR01CA161796 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 2011 to 2015
$1.6M
Signaling Pathways and Therapeutic Targeting of Leukemic CellsI01CX000916 · VA · JESSE BROWN VA MEDICAL CENTER · PI PLATANIAS, LEONIDAS C. · 2013 to 2025
–
CSRD VA I01 CX000916NCI NIH HHS CA155566NCI NIH HHS CA161796NCI NIH HHS CA77816NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA077816NCI NIH HHS R01 CA155566NCI NIH HHS R01 CA161796NCI NIH HHS T32 CA070085NCI NIH HHS T32 CA080621
6 · The paper itself

Abstract

We provide evidence for a unique pathway engaged by the type II IFN receptor, involving mTORC2/AKT-mediated downstream regulation of mTORC1 and effectors. These events are required for formation of the eukaryotic translation initiation factor 4F complex (eIF4F) and initiation of mRNA translation of type II interferon-stimulated genes. Our studies establish that Rictor is essential for the generation of type II IFN-dependent antiviral and antiproliferative responses and that it controls the generation of type II IFN-suppressive effects on normal and malignant hematopoiesis. Together, our findings establish a central role for mTORC2 in IFNγ signaling and type II IFN responses.

Indexed as

Signal TransductionAnimalsAntiviral AgentsCarrier ProteinsChemokine CXCL10Eukaryotic Initiation Factor-4FFibroblastsGene Expression RegulationHematopoiesisHematopoietic Stem CellsHumansInterferon-gammaInterferon-Stimulated Gene Factor 3, gamma SubunitMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MiceAntiviral AgentsCarrier ProteinsChemokine CXCL10Cxcl10 protein, mouseEukaryotic Initiation Factor-4FInterferon-gammainterferon receptor, type IIInterferon-Stimulated Gene Factor 3, gamma SubunitIsgf3g protein, mouseMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2Multiprotein ComplexesRapamycin-Insensitive Companion of mTOR ProteinReceptors, Interferonrictor protein, mouseTOR Serine-Threonine Kinasesantiviral agentinterferonPI3Ksignal transductiontranslation controltranslation initiation factor

Identifiers

PMID26645692
PMCPMC4732221
OpenAlexW2346942712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.